Belite Bio Inc ADR (BLTE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Belite Bio Inc ADR (BLTE) is down 15.7% since the beginning of the year. At $135 per share, BLTE is trading 32.5% below its 52-week high of $200.

Belite Bio Inc ADR (BLTE) has returned -15.65% so far this year and 107.52% over the past 12 months.

Based on dividend-adjusted daily data since Apr 29, 2022, BLTE's average daily return is +0.35%, while the average monthly return is +7.41%. At this rate, an investment would double in approximately 0.8 years.

Historically, 50% of months were positive and 50% were negative. The best month was Jun 2022 with a return of +106.0%, while the worst month was May 2023 at -43.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.

On a daily basis, BLTE closed higher 52% of trading days. The best single day was May 3, 2022 with a return of +30.8%, while the worst single day was May 31, 2023 at -31.1%.

Belite Bio Inc ADR has an annualized alpha of 131.59%, beta of 0.25, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since May 02, 2022.

• This stock captured 56.80% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -699.62%) - a profile typical of hedging or uncorrelated assets.
• Beta of 0.25 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

BLTE ranks 86 for risk / return — in the top 86% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Belite Bio Inc ADR (BLTE) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Belite Bio Inc ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Belite Bio Inc ADR was 74.59%, occurring on Jun 23, 2023. Recovery took 120 trading sessions.

The current Belite Bio Inc ADR drawdown is 29.10%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Belite Bio Inc ADR over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Belite Bio Inc ADR is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.